Holen Sie sich die Stockscreener-App
0.90
0.11%
0.001
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
Is Cue Biopharma Inc. a good long term investmentBreakthrough profits - jammulinksnews.com
What analysts say about Cue Biopharma Inc. stockBreakthrough wealth creation - jammulinksnews.com
Cue Biopharma Inc. Stock Analysis and ForecastExceptional return forecasts - jammulinksnews.com
What drives Cue Biopharma Inc. stock priceExceptional profit velocity - jammulinksnews.com
Why Cue Biopharma Inc. stock is on top investor watchlistsLong Term Safe Yield Focus - beatles.ru
Cue Biopharma shares fall 4.67% premarket despite reporting new complete response in clinical trial. - AInvest
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer - The Manila Times
Breakthrough: New Cancer Drug Shows 88% Survival Rate in Head and Neck Cancer Phase 1 Trial - Stock Titan
How Cue Biopharma Inc. stock performs during market volatilityStrong Return Daily Alerts - Newser
How Olin Corporation stock performs during market volatilityCapital Protected Stock Selections - Newser
What makes Cue Biopharma Inc. stock price move sharplyBig Return Stock Tips - Newser
Why Cue Biopharma Inc. stock attracts strong analyst attentionSwing Trade Signals - Newser
Why RAPT Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Shares - Newser
Why Starz Entertainment LLC stock attracts strong analyst attentionSmart Return Focused Trading - Newser
What makes Southside Bancshares Inc. stock price move sharplyFree Stock Market Forums - Newser
Why FTAI Infrastructure Inc. stock attracts strong analyst attentionStable Stocks With High Yield - beatles.ru
EQBK issues 1.73M shares, completes NBC merger & adds new director | XPON SEC FilingForm 8-K - Stock Titan
Funko (FNKO) CEO Cynthia Williams Resigns; Lunsford Named Interim | TBBK SEC FilingForm 8-K - Stock Titan
Head and Neck Cancer Pipeline Therapeutics Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Cue Biopharma shares fall 3.72% premarket after providing update on CUE-101 clinical trial. - AInvest
Cue Biopharma reports promising results for HPV+ head and neck cancer drug - Investing.com
Cue Biopharma Reports Promising Phase 1 Trial Results for CUE-101 in HPV+ Recurrent Metastatic Head and Neck Cancer - Nasdaq
Nasdaq Announces the Board of Directors of its U.S. Exchanges - The Manila Times
Breakthrough: New Cancer Drug Doubles Response Rate vs Standard Treatment in Head and Neck Cancer Trial - Stock Titan
Cue Biopharma Amends License Agreement with MIL 40G - TipRanks
KIDZW seeks OK for 2B share increase, $900M Solana funding plan | JXN SEC FilingForm 4 - Stock Titan
Cue Biopharma holds pre-IND meeting with FDA for lead autoimmune asset - BioWorld MedTech
CUE Receives FDA Pre-IND Feedback for CUE-401 Development | CUE Stock News - GuruFocus
Cue Biopharma's CUE-401: A Breakthrough in Autoimmune Therapies? - AInvest
Millennium Management LLC Reduces Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Bank of America Corp DE Acquires 85,113 Shares of Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
CueBiopharma (CUE) Appoints Interim CFO as Kerri-Ann Millar Resi - GuruFocus
Cue Biopharma CFO Kerri-Ann Millar to Depart - marketscreener.com
Cue Biopharma CFO Resignation and Board Appointment - TipRanks
Cue Biopharma CEO Daniel Passeri To Serve As Interim CFO - marketscreener.com
4.79%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):